How did the 2013 Myriad case change BRCA testing?

Share

Summary

This article summarizes the Supreme Court's 2013 decision in Association for Molecular Pathology v. Myriad Genetics, which ruled that naturally occurring DNA segments cannot be patented simply because they are isolated, while noting that lab-made cDNA may still be patent eligible.

Highlights

The BRCA Genes and Myriad Genetics' Patents00:00:00

Before 2013, patients seeking tests for inherited changes in BRCA1 and BRCA2 often had to use Myriad Genetics, which held patents covering those genes. The company argued patents supported research, while critics argued no company should control naturally occurring human genes.

The Supreme Court's Ruling00:02:11

On June 13, 2013, the Supreme Court unanimously ruled that a naturally occurring DNA segment does not become patentable simply because it has been isolated. The court distinguished between the discovery of a gene and the legal claim of owning it.

Complementary DNA (cDNA) and Limits00:03:08

The decision noted that lab-made complementary DNA (cDNA) can be patent eligible because it is created from a processed genetic message and usually lacks introns. However, short cDNA sequences indistinguishable from natural DNA are not made patentable just by being synthesized.

Impact on Competition and Testing00:04:16

The ruling removed a major barrier to competition, allowing other laboratories like Ambry Genetics to offer BRCA testing. This could lead to different prices and turnaround times, though it did not guarantee affordability, insurance coverage, or easy interpretation.

Interpretation and Data Sharing00:05:21

Testing involves identifying meaningful variants and explaining uncertainty. While competitors could analyze genes after the ruling, access to Myriad's accumulated variant data remained a separate issue, complicating the true meaning of access.

What the Ruling Did Not Mean00:07:28

The ruling did not mean BRCA genes were owned by everyone or that every discovery is unpatentable. It specifically addressed diagnostic testing and did not involve CRISPR or gene editing, leaving broader questions about innovation incentives and access unresolved.

Recently Summarized Articles

Loading...
Summarize another YouTube video →